Skip to content

Zymeworks ZYME Lease Liability Payments - Due Year Four

Lease Liability Payments - Due Year Four at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$14.25M
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$1.59M+59.6%
iRhythm Holdings, Inc.
 logo
iRhythm Holdings, Inc. IRTC
$17.61M+2.9%

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's lease liability payments - due year four.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's lease liability payments - due year four?
Zymeworks (ZYME) reported lease liability payments - due year four of $2.86M in Q1 2026.
How has Zymeworks's lease liability payments - due year four changed year-over-year?
Zymeworks's lease liability payments - due year four decreased by 3.4% year-over-year, from $2.96M to $2.86M.
What does lease liability payments - due year four mean?
The contractual cash obligations for operating and finance leases due in the fourth year following the balance sheet date. This is part of the long-term lease maturity schedule that helps investors assess the company's future fixed cost burden. It allows for better modeling of long-term capital allocation and cash flow stability.